Cargando…
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645291/ http://dx.doi.org/10.1186/2051-1426-3-S2-P166 |
| _version_ | 1782400800662749184 |
|---|---|
| author | Weber, Jeffrey Grob, Jean-Jaques Margolin, Kim A Ascierto, Paolo A Sznol, Mario Ott, Patrick A Lejeune, Chantal de Pril, Veerle Ruisi, Mary M Hodi, F Stephen |
| author_facet | Weber, Jeffrey Grob, Jean-Jaques Margolin, Kim A Ascierto, Paolo A Sznol, Mario Ott, Patrick A Lejeune, Chantal de Pril, Veerle Ruisi, Mary M Hodi, F Stephen |
| author_sort | Weber, Jeffrey |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645291 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46452912015-11-20 A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence Weber, Jeffrey Grob, Jean-Jaques Margolin, Kim A Ascierto, Paolo A Sznol, Mario Ott, Patrick A Lejeune, Chantal de Pril, Veerle Ruisi, Mary M Hodi, F Stephen J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645291/ http://dx.doi.org/10.1186/2051-1426-3-S2-P166 Text en Copyright © 2015 Weber et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Weber, Jeffrey Grob, Jean-Jaques Margolin, Kim A Ascierto, Paolo A Sznol, Mario Ott, Patrick A Lejeune, Chantal de Pril, Veerle Ruisi, Mary M Hodi, F Stephen A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title | A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title_full | A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title_fullStr | A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title_full_unstemmed | A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title_short | A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence |
| title_sort | phase iii study (checkmate 238) of adjuvant immunotherapy with nivolumab (nivo) versus ipilimumab (ipi) after complete resection of stage iiib/c or stage iv melanoma (mel) in patients (pts) at high risk for recurrence |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645291/ http://dx.doi.org/10.1186/2051-1426-3-S2-P166 |
| work_keys_str_mv | AT weberjeffrey aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT grobjeanjaques aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT margolinkima aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT asciertopaoloa aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT sznolmario aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT ottpatricka aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT lejeunechantal aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT deprilveerle aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT ruisimarym aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT hodifstephen aphaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT weberjeffrey phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT grobjeanjaques phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT margolinkima phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT asciertopaoloa phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT sznolmario phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT ottpatricka phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT lejeunechantal phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT deprilveerle phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT ruisimarym phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence AT hodifstephen phaseiiistudycheckmate238ofadjuvantimmunotherapywithnivolumabnivoversusipilimumabipiaftercompleteresectionofstageiiibcorstageivmelanomamelinpatientsptsathighriskforrecurrence |